Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Biotech Movers: BioCardia Surges on FDA Meeting Minutes, Clearmind Hits ...
BioCardia Shares Rally After FDA Supports Regulatory Path for Heart ...
What's going on with BioCardia stock Tuesday?
BCDA Press Release: BioCardia Announces $4.4 Million Financing
Why is BioCardia stock gaining Friday?
BioCardia Announces Pre-Submission Approval Package for Helix ...
BioCardia (BCDA) FDA Approvals, PDUFA Dates & Drug Alerts 2026
BioCardia (BCDA) Stock Latest News - BCDA News Today
BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable ...
BioCardia Reports First Quarter 2025 Business Highlights and Financial ...
Advancing Cell Therapy for Heart Failure: BioCardia Announces CardiAMP ...
BioCardia announces FDA review completion of ongoing cell therapy for ...
BioCardia Seeks Accelerated FDA Path for CardiAMP Cell Therapy in ...
BioCardia launches pivotal trial for CardiAmp heart failure treatment ...
BioCardia Announces First Patient Treated in CardiAMP Cell Therapy ...
BioCardia Announces Positive DSMB Review and Recommendation to Continue ...
BioCardia Announces Fourth Positive DSMB Review and Recommendation to ...
BioCardia Pivots to Biomarker Strategy to Prove Heart Failure Cell ...
BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene ...
BioCardia Files Pre-Submission for FDA Approval of Helix Catheter
BioCardia Completes FDA Pre-Submission for Helix Transendocardial ...
BioCardia CardiAmp trial passes safety analysis - Cardiovascular News
BioCardia Completes Phase III Clinical Trial of Autologous Stem Cell ...
BioCardia sets Q4 2025 for FDA and PMDA submissions for CardiAMP and ...
BioCardia Announces FDA Breakthrough Device Designation for CardiAMP ...
BioCardia Submits Clinical Trial to FDA for New Indication of Chronic ...
BioCardia to Present Late-Breaking CardiAMP HF Trial Data
BioCardia Announces Japanese Patent on Imaging System for Targeting ...
BioCardia Announces US Patent on Imaging System for Targeting Cardiac ...
BioCardia Announces New Center for Medicare and Medicaid Services ...
BioCardia Expands Innovations with New Japanese Patent Approval ...
BioCardia Announces FDA Completes Review of Proposed Adaptive ...
Biocardia 2025 Q3 Earnings Narrowed Losses and Regulatory Progress
Biocardia 2024 Q2 Earnings Misses Targets as Revenue Declines 93%
BioCardia Seeks Approval in Japan for Cell Therapy for Ischemic Heart ...
Biocardia (BCDA.O) Plunges 12.7%: A Technical and Order-Flow Deep Dive
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the ...
CellProthera and BioCardia announce successful results from ...
BioCardia Announces Henry Ford Health Enrolls Their First Patient in ...
Biocardia 2025 Q3 Earnings Narrowed Losses Amid Regulatory Progress
BioCardia outlines regulatory milestones and targets FDA and PMDA ...
BioCardia eyes 2026 Japan approval for heart failure therapy
Is BioCardia (NASDAQ:BCDA) In A Good Position To Deliver On Growth ...
BioCardia Investors Await Critical Quarterly Update
BioCardia rejigs phase 3 heart failure data to find a path forward
BioCardia (BCDA) Up on Plans for Second Heart Failure Study ...
BioCardia Updates on CardiAMP® and Helix™ Regulatory Timelines
**Cell Therapy**: BioCardia Earnings Call Reveals Breakthrough Results ...
BioCardia Shares FDA & PMDA Timeline for CardiAMP & Helix | Pienomial
BioCardia Enrolls First Patient in Phase 3 Trial
BioCardia Receives U.S. Patent Covering Morph Product Family Design ...
BioCardia Aims To Defy Precedent With A Cardiac Cell Therapy
BioCardia Seeks Japan PMDA Review for Heart Failure Cell Therapy ...
BioCardia
BioCardia Likely to Miss the Mark in Phase 3 CardiAMP Heart Failure ...
Mixed Data From CardiAMP Study as BioCardia Advances New Phase III ...
BioCardia Reports Third Quarter: $6M Financing, Cash $5.3M | BCDA Stock ...
BioCardia Completes Low-Dose Cohort Enrollment in CardiALLO Trial
BioCardia Pauses Patient Enrollment in Pivotal Phase 3 Cardiac Trial ...
BioCardia Advances Cell Therapy Review with Japan's PMDA | BCDA Stock News
BioCardia unveils interim data that led it to stop PhIII enrollment of ...
Boston Scientific says Biocardia doesn't own women's health patents ...
BioCardia congratulates Dr. Parag Patel and Dr. Leslie Miller of ...
Bullish BioCardia Insider Buying Worth US$1.06m Yet To Pay Off
Biocardia Receives US Patent Covering a Method of Preparing and ...
BioCardia Announces First UW Patient in Phase 3 CardiAMP HF II | BCDA ...
BioCardia Starts CardiAMP HF II Patient Enrollment at Emory
BioCardia Receives FDA Breakthrough Device Designation for CardiAMP ...
Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for ...
Biocardia Helix Biotherapeutic Delivery System
Why Did BCDA Stock Surge More Than 50% Today?
Tango Therapeutics Stock Rockets on Standout Pancreatic Cancer Results ...
IPO lock-up exemptions | Hudson Labs
BioCardia, Inc. (BCDA) Stock Price, News, Quote & History - Yahoo Finance
BCDA Q1 2026 Earnings Report on 5/15/2026
Phone: 650-226-0120
Hemostemix Inc.: Hemostemix Announces its 10th Publication: A Molecular ...
Breakthrough designation granted to CardiaAMP cell therapy system for ...
BioCardia's off-the-shelf cell therapy for heart failure to enter first ...
BioCardia: CardiAMP System to Treat Heart Failure
BioCardia's CardiAMP Cell Therapy: A Regenerative Breakthrough for ...
We have treated the first patient in the CardiAMP HF II trial at ...
BioCardia, Inc. Q4 2025 Earnings Call Summary
Empowered Patient Podcast: Autologous Cell Therapy for Heart Disease ...
Biocardia's 21% Plunge: A Bearish Storm Amid Capital Raise and Clinical ...
BioCardia’s CardiAMP HF II Phase 3 Trial Reaches Milestone With First ...
BioCardia's Q1 2025: Unpacking Key Contradictions in Japan Strategy and ...
BioCardia's Q3 2025 Earnings Call: Contradictions Emerge on Japan ...
BioCardia, Inc. Secures Japanese Patent for Innovative Catheter ...
BioCardia’s Unexpected Market Fluctuation: Opportunities?
BioCardia's Q4 2025 Regulatory Milestones and Their Market Implications
BioCardia’s Hidden Catalysts: Why Cardiac Regenerative Medicine’s Next ...
BioCardia's Q3 2025: Contradictions Emerge on Japan Regulatory Hurdles ...
BioCardia, Inc. (NASDAQ:BCDA) Q3 2024 Earnings Call Transcript ...
BioCardia's $12M Raise: A Strategic Move to Accelerate Regenerative ...
Autologous Cell Therapy for Heart Disease Transformed with Point-of ...
BioCardia's Q4 2024: Regulatory Contradictions in CardiAMP's Japan ...
BioCardia’s Funding Fuels Progress For Its Heart Therapy - Finimize
Marketing Mix Analysis of BioCardia, Inc. (BCDA) – DCFmodeling.com
BioCardia's CardiAMP Cell Therapy for Heart Failure Receives FDA Review ...
Stem Cells for Heart Failure? BioCardia's CardiAMP Pairs Cells, Devices ...
Preliminary Results From BioCardia's Phase III Pivotal CardiAMP Heart ...
Successful Transendocardial Delivery of Autologous Cells for Ischemic ...
BioCardia’s Pivotal Heart Failure Trial Enrolls First Patient
CardiAMP Cell Therapy Receives FDA Approval for Pivotal Trial in ...
Positive Data On BioCardia's Investigational CardiAMP Cell Therapy For ...
Autologous Angiogenic Cell Precursors- A Molecular Strategy for the ...
细胞疗法治疗心衰：BioCardia_腾讯新闻
BioCardia’s CardiAMP HF II Phase 3 Trial: First Patient Enrolled at ...
